Electrification in life sciences is emerging as a strategic imperative beyond mere carbon reduction. New research reveals it significantly strengthens resilience, reduces operating costs, and enhances ...

Wave Life Sciences (WVE) stock analysis: low valuation (2.45x cash, no debt) vs. RNA therapy competition; key upside tied to WVE-N531 results. See more here.

Nominations are now open for the 2026 Fiercest Women in Life Sciences. | Who should be a 2026 Fiercest Woman in Life Sciences ...

Black Book Research and Applied Artificial Intelligence LLC identify 2026-2027 client-rated technology leaders across 28 ...

A ccording to the CBRE U.S. Life Sciences Outlook 2025 report, U.S life sciences employment hit a record high in 2024, and more job growth is expected in 2025. Meanwhile, the life sciences sector ...

Life sciences businesses are very healthy these days. Advances in research, testing, and manufacturing in the pharmaceutical, biotech, medical devices, and related industries continue to generate high ...

Through this collaboration, users can analyze Carelon Real World Data (RWD) alongside third-party datasets without moving data outside their respective organizations, reducing risk and strengthening ...

Johns Hopkins University will invest $80 million annually for each of the next two years in groundbreaking basic and applied research across a vast array of life science disciplines—from immunology to ...

BHUBANESWAR: Science and Technology minister Krushna Chandra Patra on Tuesday met Union minister of state for Science and Technology and Earth Sciences, Atomic Energy and Space Jitendra Singh in New ...

Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or th ...

As costs and regulatory pressures rise and educated patients clamor for personalized treatment, digital innovations will inexorably alter the life sciences landscape. Michael Townsend, research ...

Sellas Life Sciences (SLS) reported a Q2 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier. Two analysts polled by FactSet expected a loss of $0.05. As of ...